Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137668 · ClinicalTrials.gov registry record · Phase 1
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
A Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia, sponsored by Sacramento Pediatric Gastroenterology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT02137668 is a Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia that is actively recruiting participants, run by Sacramento Pediatric Gastroenterology. The registered enrollment target is 200 participants, below the 544-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02137668, a Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia, is actively recruiting participants, sponsored by Sacramento Pediatric Gastroenterology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Conditions Studied
Interventions
- DRUG Oral Vancomycin
Study Locations (1)
California
- Sacramento Pediatric Gastroenterology - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2010-07 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02137668
The ClinicalTrials.gov registry entry for NCT02137668 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 544-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (63% lower). The listed sponsor is Sacramento Pediatric Gastroenterology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 1 intervention - of which Oral Vancomycin is the first listed.
NCT02137668 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02137668 about?
NCT02137668 is a clinical study titled "Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin". The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions ...
What is the current status of trial NCT02137668?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2010-07. Estimated completion is 2028-07.
What conditions does trial NCT02137668 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis, Biliary Atresia.
What interventions are being tested in trial NCT02137668?
The interventions under investigation include: Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT02137668?
This trial is sponsored by Sacramento Pediatric Gastroenterology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02137668 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
RECRUITING · Phase 1
-
A Study of SIPLIZUMAB in AILD and LT Patients
RECRUITING · Phase 1
-
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
COMPLETED · Phase 1
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.